vs

Side-by-side financial comparison of Insight Molecular Diagnostics Inc. (IMDX) and REZOLVE AI PLC (RZLV). Click either name above to swap in a different company.

REZOLVE AI PLC is the larger business by last-quarter revenue ($1.2M vs $1.1M, roughly 1.1× Insight Molecular Diagnostics Inc.). REZOLVE AI PLC runs the higher net margin — -1078.8% vs -2015.4%, a 936.6% gap on every dollar of revenue.

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

REZOLVE AI PLC is a UK-based technology firm developing AI-powered mobile engagement and instant transaction platforms. Its solutions let consumers complete purchases directly from audio, video, and print content, serving retail, consumer goods, and media clients across Europe, North America, and select APAC markets.

IMDX vs RZLV — Head-to-Head

Bigger by revenue
RZLV
RZLV
1.1× larger
RZLV
$1.2M
$1.1M
IMDX
Higher net margin
RZLV
RZLV
936.6% more per $
RZLV
-1078.8%
-2015.4%
IMDX

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
IMDX
IMDX
RZLV
RZLV
Revenue
$1.1M
$1.2M
Net Profit
$-23.0M
$-13.0M
Gross Margin
42.5%
Operating Margin
-2057.5%
-808.4%
Net Margin
-2015.4%
-1078.8%
Revenue YoY
-23.4%
Net Profit YoY
31.5%
EPS (diluted)
$-0.75

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMDX
IMDX
RZLV
RZLV
Q4 25
$1.1M
Q3 25
$260.0K
Q2 25
$518.0K
$1.2M
Q1 25
$2.1M
Q4 24
$1.5M
Q3 24
$115.0K
Q2 24
$104.0K
Q1 24
$176.0K
Net Profit
IMDX
IMDX
RZLV
RZLV
Q4 25
$-23.0M
Q3 25
$-10.9M
Q2 25
$-9.7M
$-13.0M
Q1 25
$-6.7M
Q4 24
$-33.5M
Q3 24
$-13.5M
Q2 24
$-4.5M
Q1 24
$-9.1M
Gross Margin
IMDX
IMDX
RZLV
RZLV
Q4 25
42.5%
Q3 25
53.5%
Q2 25
67.6%
Q1 25
62.0%
Q4 24
40.0%
Q3 24
43.5%
Q2 24
48.1%
Q1 24
25.6%
Operating Margin
IMDX
IMDX
RZLV
RZLV
Q4 25
-2057.5%
Q3 25
-4249.2%
Q2 25
-1900.0%
-808.4%
Q1 25
-318.0%
Q4 24
-2262.9%
Q3 24
-11752.2%
Q2 24
-4453.8%
Q1 24
-5265.3%
Net Margin
IMDX
IMDX
RZLV
RZLV
Q4 25
-2015.4%
Q3 25
-4174.6%
Q2 25
-1880.7%
-1078.8%
Q1 25
-312.0%
Q4 24
-2255.1%
Q3 24
-11733.0%
Q2 24
-4355.8%
Q1 24
-5186.9%
EPS (diluted)
IMDX
IMDX
RZLV
RZLV
Q4 25
$-0.75
Q3 25
$-0.34
Q2 25
$-0.30
Q1 25
$-0.26
Q4 24
$-2.19
Q3 24
$-0.98
Q2 24
$-0.36
Q1 24
$-1.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMDX
IMDX
RZLV
RZLV
Cash + ST InvestmentsLiquidity on hand
$11.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$-31.5M
$-14.3M
Total Assets
$25.8M
$80.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMDX
IMDX
RZLV
RZLV
Q4 25
$11.6M
Q3 25
$18.7M
Q2 25
$24.3M
Q1 25
$31.0M
Q4 24
$8.6M
Q3 24
$3.4M
Q2 24
$9.3M
Q1 24
$5.6M
Stockholders' Equity
IMDX
IMDX
RZLV
RZLV
Q4 25
$-31.5M
Q3 25
$-9.2M
Q2 25
$1.1M
$-14.3M
Q1 25
$10.2M
Q4 24
$-12.3M
Q3 24
$9.7M
Q2 24
$22.7M
Q1 24
$11.6M
Total Assets
IMDX
IMDX
RZLV
RZLV
Q4 25
$25.8M
Q3 25
$43.9M
Q2 25
$50.5M
$80.1M
Q1 25
$60.4M
Q4 24
$35.1M
Q3 24
$70.2M
Q2 24
$74.7M
Q1 24
$71.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMDX
IMDX
RZLV
RZLV
Operating Cash FlowLast quarter
$-5.5M
$-4.9M
Free Cash FlowOCF − Capex
$-7.0M
FCF MarginFCF / Revenue
-616.7%
Capex IntensityCapex / Revenue
129.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMDX
IMDX
RZLV
RZLV
Q4 25
$-5.5M
Q3 25
$-4.5M
Q2 25
$-6.3M
$-4.9M
Q1 25
$-5.9M
Q4 24
$-5.4M
Q3 24
$-5.5M
Q2 24
$-6.0M
Q1 24
$-3.8M
Free Cash Flow
IMDX
IMDX
RZLV
RZLV
Q4 25
$-7.0M
Q3 25
$-5.6M
Q2 25
$-6.6M
Q1 25
$-6.2M
Q4 24
$-5.6M
Q3 24
$-5.6M
Q2 24
$-6.2M
Q1 24
$-3.9M
FCF Margin
IMDX
IMDX
RZLV
RZLV
Q4 25
-616.7%
Q3 25
-2135.4%
Q2 25
-1279.5%
Q1 25
-288.4%
Q4 24
-374.5%
Q3 24
-4884.3%
Q2 24
-5931.7%
Q1 24
-2189.8%
Capex Intensity
IMDX
IMDX
RZLV
RZLV
Q4 25
129.9%
Q3 25
403.8%
Q2 25
67.4%
Q1 25
14.4%
Q4 24
14.4%
Q3 24
75.7%
Q2 24
183.7%
Q1 24
13.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons